Erratum to “Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease” [Journal of Diabetes and Its Complications 28 (2014) 711–714]

2015 ◽  
Vol 29 (1) ◽  
pp. 158
Author(s):  
Da-jun Lou ◽  
Qi-qian Zhu ◽  
Xu-wei Si ◽  
Li-li Guan ◽  
Qiao-ying You ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Fatty Acids ◽  
Fatty Liver Disease ◽  
Omega 3 ◽  
Serum Phospholipid ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals A Prospective Study of Ultrasonographic Assessment of Non-Alcoholic Fatty Liver Disease (Steatosis) Among Type 2 Diabetes Mellitus With Liver Function Test Correlation

2020 ◽  
Vol 11 (4) ◽  
pp. 7102-7107
Author(s):  
Kisshore Kumar G ◽  
Praveen K Sharma ◽  
Karthik Krishna Ramakrishnan ◽  
Seena Cheppala Rajan
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Enzymes ◽  
Alcoholic Fatty Liver ◽  
Function Test ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) emerging condition of liver disease. Prevalence of this disease is estimated to be around 9-32% among Indian population with increased incidence rate among obese and diabetes. Insulin resistance is strongly associated with NAFLD. The spectrum varies from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH), finally to cirrhosis. It has been regarded as a manifestation of the metabolic syndrome. Ultrasonography (USG) is the simplest and cost-effective imaging technique for the identification of NAFLD. The Aminotransferase levels were also significantly elevated among T2DM. The results from the study reinforced the well established clinical association of NAFLD with higher Aminotransferase levels among T2DM. NAFLD may be considered as the hepatic hallmark of insulin resistance, and its correlation with liver enzymes, an excellent marker to predict disease outcome. This study is conducted to establish the prevalence of(NAFLD) among type 2 Diabetes mellitus (T2DM) along with Liver function test (Aminotransferase levels) correlation. The results from the study reinforced the well established clinical association of NAFLD with other co-morbidities like dyslipidemia, obesity, metabolic syndrome as the prevalence of NAFLD in these co-morbidities condition had a higher level rise in aminotransferases.The prevalence of NAFLD among T2DM in our study is higher when compared with other studies. NAFLD may be considered as a hepatic hallmark of insulin resistance and correlating it with alteration in liver enzymes will be an excellent marker to predict disease outcome.

scholarly journals Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

2021 ◽  
Vol 12 ◽  
pp. 204201882110002
Author(s):  
Taeang Arai ◽  
Masanori Atsukawa ◽  
Akihito Tsubota ◽  
Shigeru Mikami ◽  
Hiroki Ono ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Propensity Score ◽  
Fatty Liver Disease ◽  
Liver Inflammation ◽  
Alcoholic Fatty Liver ◽  
Sodium Glucose Cotransporter ◽  
Alcoholic Fatty Liver Disease

Background: Although sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve not only glycemic control but also liver inflammation and fatty changes in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM), its sustainability and effect on liver fibrosis have remained unclear. The current study aimed to clarify the effects of 48-week SGLT2-I therapy on liver inflammation, fatty changes, and fibrosis in NAFLD patients with T2DM. Methods: This study evaluated the effects of SGLT2-I on NAFLD, including liver fibrosis assessed via transient elastography, in 56 patients with NAFLD who received SGLT2-I for 48 weeks. Moreover, changes in each clinical parameter between patients receiving SGLT2-I (the SGLT2-I group) and those receiving other oral hypoglycemic agents (OHAs) (the non-SGLT2-I group) were compared, using 1:1 propensity score matching to adjust for baseline factors. Results: The SGLT2-I group exhibited a significant decrease in controlled attenuation parameter (312 dB/m at baseline to 280 dB/m at week 48) and liver stiffness measurement (9.1–6.7 kPa) ( p < 0.001 for both). After propensity score matching (44 patients each in the SGLT2-I and non-SGLT2-I groups), no significant difference in HbA1c decrease was observed between the two groups. However, compared with the non-SGLT2-I group, the SGLT2-I group showed a significant decrease in body weight ( p < 0.001), alanine aminotransferase ( p = 0.02), uric acid ( p < 0.001), and Fibrosis-4 (FIB-4) index ( p = 0.01) at week 48. The improvement in FIB-4 index, defined as a ⩾10% decline from baseline at week 48, was 56.8% (25/44) in the SGLT2-I group and 20.5% (9/44) in the non-SGLT2-I group ( p < 0.001). Conclusion: SGLT2-Is improved not only glycemic control but also liver fatty infiltration and fibrosis in patients with NAFLD and T2DM, suggesting their possible superiority to other OHAs concerning these effects.

scholarly journals Non-Alcoholic Fatty Liver Disease among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia

2018 ◽  
Vol 15 (11) ◽  
pp. 2521 ◽  
Author(s):  
Abdullah Alsabaani ◽  
Ahmed Mahfouz ◽  
Nabil Awadalla ◽  
Mustafa Musa ◽  
Suliman Al Humayed
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Dietary Control ◽  
Alcoholic Fatty Liver ◽  
Factors Associated ◽  
Alcoholic Fatty Liver Disease

The objective of this study was to determine the prevalence and the factors associated with non-alcoholic fatty liver disease (NAFLD) among type-2 diabetes mellitus (T2DM) patients in Abha City, Southwestern Saudi Arabia. Using a cross-sectional study design, a representative sample of 245 T2DM patients were recruited from all primary healthcare centers in Abha city. A detailed medical history as well as laboratory investigations were done. NAFLD was diagnosed using abdominal ultrasound examination. The overall prevalence of NAFLD was 72.8% (95% CI: 66.6%–78.1%). In a multivariable regression analysis, the risk of NAFLD was significantly higher among overweight T2DM patients (aOR = 6.112, 95% CI: 1.529–4.432), Obese (aOR = 10.455, 95% CI: 2.645–41.326), with high ALT of more than 12 IU/L (aOR = 2.335, 95% CI: 1.096–5.062), moderate diet-compliant patients (aOR = 2.413, 95% CI: 1.003–5.805) and poor diet-compliant patients (aOR = 6.562, 95% CI: 2.056–20.967). On the other hand, high HDL (high density cholesterol) (in mg/dL) was a protective factor for NAFLD (aOR = 0.044, 95% CI: 0.005–0.365). It was concluded that NAFLD is a common association of T2DM. Increasing BMI (Body mass index), lower HDL level, and poor dietary control are significant factors associated with NAFLD among T2DM patients. Health education to improve dietary control and avoid excessive weight gain, testing for NAFLD among diabetic patients, especially those with abnormal BMI and HDL, are recommended for early detection and to ensure optimal levels of HDL.

Sign in / Sign up

Export Citation Format

Share Document